Notice2026-12070
Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 115 (Tuesday, June 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 115 (Tuesday, June 16, 2026)]
[Notices]
[Page 36152]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-12070]
[[Page 36152]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for License: Establishment
and Characterization of the A1847 Human Ovarian Carcinoma Line
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute (NCI) seeks licensees for a
tumorigenic cell line, A1847, from a patient with metastatic ovarian
cancer. As a BRCA1 deficient cell line, it serves as a model to
researchers studying cell cycle regulation, tumor suppression and
effective drugs aiding in repair of DNA damage.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this license
opportunity should be directed to: Suna Gulay French, Ph.D., Technology
Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#0172746f602f66746d6078416f68692f666e77"><span class="__cf_email__" data-cfemail="1360667d723d74667f726a537d7a7b3d747c65">[email protected]</span></a> or Phone: 240-276-7424.
SUPPLEMENTARY INFORMATION: Mutations, such as loss of function, in the
BRCA1 gene increase the risk of developing ovarian cancer. In its early
stages, ovarian cancer may not cause any definitive symptoms but can
rapidly progress within a year to advanced stage. This metastatic
growth can occur by shedding cancerous cells into peritoneal fluid,
often associated with epithelial ovarian cancer, its most common type.
While treatments exist, it is limited by the development of drug
resistance that is not succumbed to damage in cell death.
The National Cancer Institute (NCI) researchers derived a
metastatic ovarian carcinoma cell line, A1847, from a 50-year-old
female. It was established as a continuous tumorigenic cell line and
characterized by isozyme phenotype, short tandem repeat (STR) analysis
and karyotypically with modal number 68 and 3 marker chromosomes. This
cell line may be used to identify therapeutic targets and to screen
drug candidates against ovarian cancer.
NCI is seeking parties to nonexclusively license the A1847 human
ovarian carcinoma cell line. ``This Notice is in accordance with 37 CFR
404.4 Authority to grant licenses.''
NIH Reference Number: E-137-2023-0.
Related Technologies: E-018-2020-0.
Product Type: Research Material/Tool.
Therapeutic Area(s): Oncology.
Publications:
<bullet> Standing, D., et al. Selective targeting of IRAK1
attenuates low molecular weight hyaluronic acid-induced stemness and
non-canonical STAT3 activation in epithelial ovarian cancer. (PMID
38796478).
<bullet> Sethi, G., et al. An RNA interference lethality screen of
the human druggable genome to identify molecular vulnerabilities in
epithelial ovarian cancer. (PMID 23056589).
<bullet> Godwin, A.K., et al. High resistance to cisplatin in human
ovarian cancer cell lines is associated with marked increase of
glutathione synthesis. (PMID 1348364.)
Potential Commercial Applications:
<bullet> Tool to conduct preclinical proof-of-concept studies
required for commercial development of anti-cancer agents and targeted
therapies in ovarian cancer.
<bullet> Research model to investigate epithelial ovarian cancer.
<bullet> Research model for mechanistic studies of ovarian cancer
and BRCA1-deficient tumors.
Competitive Advantages:
<bullet> Well-characterized metastatic ovarian cancer cell line.
<bullet> Tumorigenic cell line to generate animal models of
metastatic ovarian cancer for commercial and research development.
Collaboration Opportunity: Researchers at the NCI seek licensing
for the A1847 ovarian cancer cell line.
Dated: June 10, 2026.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2026-12070 Filed 6-15-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.